Idorsia will conduct a proof-of-concept study for patients with vitiligo. Unique precision medicine with a dual targeting of ...

Redwood Trust, Inc. today announced the pricing of an underwritten public offering of $90,000,000 aggregate principal amount of its 9.125% senior notes due 2030 (the "Notes"). In connection with the ...